Pramipexole is active in depression tests and modulates monoaminergic transmission, but not brain levels of BDNF in mice

European Journal of Pharmacology

Volumn 677, Issue 1-3, 2012, Pages 77-86

  Schulte Herbrüggen, Olaf ^a   Vogt, Miriam A ^b   Hörtnagl, Heide ^a   Gass, Peter ^b   Hellweg, Rainer ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

5 HT; BDNF; Depression; Dopamine; Monoamines; Mouse; Pramipexole

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; IMIPRAMINE; NORADRENALIN; PRAMIPEXOLE; SEROTONIN; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; BRAIN LEVEL; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC SYSTEM; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; LONG TERM CARE; MALE; MOUSE; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SHORT COURSE THERAPY; TREATMENT DURATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZOTHIAZOLES; BIOGENIC MONOAMINES; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DOPAMINE AGONISTS; EMOTIONS; HINDLIMB SUSPENSION; MICE; MICE, INBRED C57BL; NEURONAL PLASTICITY; SYNAPTIC TRANSMISSION; TIME FACTORS;

EID: 84856278979     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.12.014     Document Type: Article

References (58)

1. I. Allaman, H. Fiumelli, P.J. Magistretti, and J.L. Martin Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes Psychopharmacology 216 2011 75 84
2. C.A. Altar Neurotrophins and depression Trends Pharmacol. Sci. 20 1999 59 61 (Pubitemid 29323957)
3. K.J. Black, T. Hershey, J.M. Koller, T.O. Videen, M.A. Mintun, J.L. Price, and J.S. Perlmutter A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist Proc. Natl. Acad. Sci. U. S. A. 99 2002 17113 17118 (Pubitemid 36034107)
4. M.E. Breuer, L. Groenink, R.S. Oosting, E. Buerger, M. Korte, B. Ferger, and B. Olivier Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats Eur. J. Pharmacol. 616 2009 134 140
5. P. Bxarone, W. Poewe, S. Albrecht, C. Debieuvre, D. Massey, O. Rascol, E. Tolosa, and D. Weintraub Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial Lancet Neurol. 9 2010 573 580
6. V. Carola, F. D'Olimpio, E. Brunamonti, F. Mangia, and P. Renzi Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behavior in inbred mice Behav. Brain Res. 134 2002 49 57 (Pubitemid 34912685)
7. S. Chaviaras, P. Mak, D. Ralph, L. Krishnan, and J.H. Broadbear Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test Psychopharmacology 210 2010 35 43
8. O. Chemoloz, M. El Mansari, and P. Blier Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain Neuropsychopharmacology 34 2009 651 661
9. P. Chiaroni, J.M. Azorin, D. Dassa, J.M. Henry, S. Giudicelli, Y. Malthiery, and R. Planells Possible involvement of the dopamine D3 receptor locus in subtypes of bipolar affective disorder Psychiatr. Genet. 10 2000 43 49 (Pubitemid 30345192)
10. S. Chourbaji, R. Hellweg, D. Brandis, B. Zorner, C. Zacher, U.E. Lang, F.A. Henn, H. Hörtnagl, and P. Gass Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior Brain Res. Mol. Brain Res. 121 2004 28 36 (Pubitemid 38224167)
11. S. Chourbaji, C. Zacher, C. Sanchis-Segura, R. Spanagel, and P. Gass Social and structural housing conditions influence the development of a depressive-like phenotype in the learned helplessness paradigm in male mice Behav. Brain Res. 164 2005 100 106 (Pubitemid 41253738)
12. N. Clausius, C. Born, and H. Grunze The relevance of dopamine agonists in the treatment of depression Neuropsychiatry 23 2009 15 25
13. J.F. Cryan, and C. Mombereau In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice Mol. Psychiatry 9 2004 326 357 (Pubitemid 38534696)
14. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol. Sci. 23 2002 238 245 (Pubitemid 34465544)
15. J.F. Cryan, C. Mombereau, and A. Vassout The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice Neurosci. Biobehav. Rev. 29 2005 571 625 (Pubitemid 40755457)
16. J.F. Cryan, M.E. Page, and I. Lucki Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment Psychopharmacology (Berl) 182 2005 335 344 (Pubitemid 41464645)
17. S. Dhillon, L.P. Yang, and M.P. Curran Bupropion: a review of its use in the management of major depressive disorder Drugs 68 2008 653 689 (Pubitemid 351484811)
18. F. Du, R. Li, Y. Huang, X. Li, and W. Le Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons Eur. J. Neurosci. 22 2005 2422 2430 (Pubitemid 41758985)
19. R.S. Duman, G.R. Heninger, and E.J. Nestler A molecular and cellular theory of depression Arch. Gen. Psychiatry 54 1997 597 606 (Pubitemid 27306570)
20. R.S. El Mallakh, P. Penagaluri, A. Kantamneni, Y. Gao, and R.J. Roberts Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review Psychiatr. Q. 81 2010 207 213
21. G. Emilien, J.M. Maloteaux, M. Geurts, K. Hoogenberg, and S. Cragg Dopamine receptors-physiological understanding to therapeutic intervention potential Pharmacol. Ther. 84 1999 133 156 (Pubitemid 29488548)
22. L.J. Felice, J.D. Felice, and P.T. Kissinger Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography J. Neurochem. 31 1978 1461 1465 (Pubitemid 9049849)
23. A.A. Gershon, T. Vishne, and L. Grunhaus Dopamine D2-like receptors and the antidepressant response Biol. Psychiatry 61 2007 145 153 (Pubitemid 46072787)
24. J.O. Groves Is it time to reassess the BDNF hypothesis of depression? Mol. Psychiatry 12 2007 1079 1088 (Pubitemid 350191365)
25. R. Hellweg, C. Hock, and H.D. Hartung An improved rapid and highly sensitive enzyme immunoassay for nerve growth factor Tech. J. Meth. Cell Mol. Biol. 1 1989 43 48
26. R. Hellweg, C.A. von Arnim, M. Buchner, R. Huber, and M.W. Riepe Neuroprotection and neuronal dysfunction upon repetitive inhibition of oxidative phosphorylation Exp. Neurol. 183 2003 346 354 (Pubitemid 37205077)
27. R. Hellweg, P. Lohmann, R. Huber, A. Kühl, and M.W. Riepe Spatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment Learn. Mem. 13 2006 63 71 (Pubitemid 43204397)
28. R. Hellweg, M. Zueger, K. Fink, H. Hörtnagl, and P. Gass Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas Neurobiol. Dis. 25 2007 1 7 (Pubitemid 44773792)
29. K. Imamura, T. Takeshima, K. Nakaso, S. Ito, and K. Nakashima Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity Neurosci. Lett. 440 2008 97 102
30. T. Inoue, Y. Kitaichi, T. Masui, S. Nakagawa, S. Boku, T. Tanaka, K. Suzuki, Y. Nakato, R. Usui, and T. Koyama Pramipexole for stage 2 treatment-resistant major depression: an open study Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 1446 1449
31. A.V. Kulikov, M.V. Morozova, V.A. Kulikov, V.S. Kirichuk, and N.K. Popova Automated analysisof antidepressants' effect in the forced swim test J. Neurosci. Meth. 191 2010 26 31
32. C.H. Lammers, J. Diaz, J.C. Schwartz, and P. Sokoloff Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments Mol. Psychiatry 5 2000 378 388 (Pubitemid 30455951)
33. L. Lattanzi, L. Dell'Osso, P. Cassano, S. Pini, P. Rucci, P.R. Houck, A. Gemignani, G. Battistini, A. Bassi, M. Abelli, and G.B. Cassano Pramipexole in treatment-resistant depression: a 16-week naturalistic study Bipolar Disord. 4 2002 307 314
34. D. Levesque, J. Diaz, C. Pilon, M.P. Martres, B. Giros, E. Souil, D. Schott, J.L. Morgat, J.C. Schwartz, and P. Sokoloff Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N, N-di-n-propyl-2-aminotetralin Proc. Natl. Acad. Sci. U. S. A. 89 1992 8155 8159
35. J. Maj, M. Dziedzicka-Wasylewska, R. Rogoz, and Z. Rogoz Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain Eur. J. Pharmacol. 351 1998 31 37 (Pubitemid 28300300)
36. J.E. Malberg, and J.A. Blendy Antidepressant action: to the nucleus and beyond Trends Pharmacol. Sci. 26 2005 631 638 (Pubitemid 41636308)
37. K. Martinowich, and B. Lu Interaction between BDNF and serotonin: role in mood disorders Neuropsychopharmacology 33 2008 73 83 (Pubitemid 350191318)
38. S.A. Montgomery Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders Int. Clin. Psychopharmacol. 17 Suppl 4 2002 S9 S15
39. F. Okada Why can low doses of sulpiride counteract depression? J. Clin. Psychopharmacol. 15 1995 442 443 (Pubitemid 26005594)
40. M. Papp, and J. Wieronska Antidepressant-like activity of amisulpride in two animal models of depression J. Psychopharmacol. 14 2000 46 52 (Pubitemid 30156538)
41. B. Petit-Demouliere, F. Chenu, and M. Bourin Forced swimming test in mice: a review of antidepressant activity Psychopharmacology (Berl) 177 2005 245 255 (Pubitemid 40137284)
42. W. Poewe, O. Rascol, P. Barone, R.A. Hauser, Y. Mizuno, M. Haaksma, L. Salin, N. Juhel, A.H. Shapira For the Pramipexole ER Studies Group Extended release pramipexole in early Parkinson disease: a 33-week randomized controlled trial Neurology 77 2011 759 766
43. D.D. Pollak, C.E. Rey, and F.J. Monje Rodent models in depression research: classical strategies and new directions Ann. Med. 42 2010 252 264
44. S. Porcelli, A. Drago, C. Fabbri, and A. Serretti Mechanisms of antidepressant action: an integrated dopaminergic perspective Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1532 1543
45. S. Ridder, S. Chourbaji, R. Hellweg, A. Urani, C. Zacher, W. Schmid, M. Zink, H. Hörtnagl, H. Flor, F.A. Henn, G. Schutz, and P. Gass Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions J. Neurosci. 25 2005 6243 6250 (Pubitemid 40923491)
46. J.I. Rossato, L.R. Bevilaqua, I. Izquierdo, J.H. Medina, and M. Cammarota Dopamine controls persistence of long-term memory storage Science 325 2009 1017 1020
47. A.A. Russo-Neustadt, and M.J. Chen Brain-derived neurotrophic factor and antidepressant activity Curr. Pharm. Des. 11 2005 1495 1510 (Pubitemid 40691448)
48. O. Schulte-Herbrüggen, S. Chourbaji, H. Muller, H. Danker-Hopfe, C. Brandwein, P. Gass, and R. Hellweg Differential regulation of nerve growth factor and brain-derived neurotrophic factor in a mouse model of learned helplessness Exp. Neurol. 202 2006 404 409 (Pubitemid 44711900)
49. O. Schulte-Herbrüggen, S. Chourbaji, S. Ridder, C. Brandwein, P. Gass, H. Hörtnagl, and R. Hellweg Stress-resistant mice overexpressing glucocorticoid receptors display enhanced BDNF in the amygdala and hippocampus with unchanged NGF and serotonergic function Psychoneuroendocrinology 31 2006 1266 1277 (Pubitemid 44803085)
50. O. Schulte-Herbrüggen, R. Hellweg, S. Chourbaji, S. Ridder, C. Brandwein, P. Gass, and H. Hörtnagl Differential regulation of neurotrophins and serotonergic function in mice with genetically reduced glucocorticoid receptor expression Exp. Neurol. 204 2007 307 316 (Pubitemid 46343725)
51. O. Schulte-Herbrüggen, E. Fuchs, N. Abumaria, E. Ziegler, H. Danker-Hopfe, C. Hiemke, and R. Hellweg Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress J. Neurosci. Res. 87 2009 2511 2560
52. P. Sokoloff, B. Giros, M.P. Martres, M.L. Bouthenet, and J.C. Schwartz Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics Nature 347 1990 146 151
53. G. Sperk Simultaneous determination of serotonin, 5-hydroxindoleacetic acid, 3,4-dihydroxyphenylacetic acid and homovanillic acid by high performance liquid chromatography with electrochemical detection J. Neurochem. 38 1982 840 843 (Pubitemid 12120626)
54. G. Sperk, M. Berger, H. Hörtnagl, and O. Hornykiewicz Kainic acid-induced changes of serotonin and dopamine metabolism in the striatum and substantia nigra of the rat Eur. J. Pharmacol. 74 1981 279 286 (Pubitemid 11008354)
55. M.A. Vogt, S. Chourbaji, C. Brandwein, C. Dormann, R. Sprengel, and P. Gass Suitability of tamoxifen-induced mutagenesisfor behavioral phenotyping Exp. Neurol. 211 2008 25 33
56. S.N. Williams, and A.S. Undieh Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression Neuroreport 20 2009 606 610
57. P. Willner Dopamine and depression: a review of recent evidence. I. Empirical studies Brain Res. 287 1983 211 224 (Pubitemid 14213761)
58. M.D. Wood, and P.B. Wren Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders Prog. Brain Res. 172 2008 213 230